Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602661 | 1.00 | OPRM1 (0.53) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2224231 | 0.98 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20744290 | 0.98 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30305364 | 0.98 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Formic Acid SCHEMBL3905110 | 0.92 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL9023712 | 0.87 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL24455261 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1CYP1A2 | |
| SCHEMBL536677 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1CYP1A2 | |
| SCHEMBL537135 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL29980976 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11352357-B2 | Cycloalkylurea derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-03-17 | — | — | US | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
| US-5641777-A | NEUROKININ RECEPTOR ANTAGONIST | SANOFI (FR) | 1997-06-24 | — | — | US | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| WO-1996023787-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-08-08 | — | — | WO | disclosed |
| EP-0700386-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026338-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
| EP-0027928-B1 | PIPERIDINE DERIVATIVES OF 4,5-DIALKYL-3-HYDROXY-PYRROLE-2-CARBOXYLIC ACID ESTERS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1983-03-09 | — | — | EP | disclosed |
| US-4315939-A | Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, pharmaceutical formulations containing these compounds and use in treating cardiac arrhythmias | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0027928-A2 | Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, their preparation and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | OPRM1 2548/4885OPRD1 1183/4885OPRK1 648/4885 |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JAK1, JAK2, JAK3 | OPRM1 2548/4885OPRD1 1183/4885OPRK1 648/4885 |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | OPRM1 2548/4885OPRD1 1183/4885OPRK1 648/4885 |
| US-11352357-B2 | Cycloalkylurea derivative | HCRTR2, HCRTR1, CRHR2 | OPRM1 170/4885OPRD1 125/4885OPRK1 79/4885 |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | HCRTR2, HCRTR1, CRHR2 | OPRM1 170/4885OPRD1 125/4885OPRK1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.